SCHEMBL2218675

SCHEMBL2218675

COC(=O)C(O)(CO)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GLA P06280 1/20 0.43
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
TET2 Q6N021 1/20 0.32
DGAT1 O75907 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16863947 0.82 GAA (0.47) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL7700768 0.82 GAA (0.47) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL31410480 0.78 GAA (0.53) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL5704826 0.75 GAA (0.43) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL24802924 0.75 GAA (0.43) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL8670899 0.74 DGAT1 (0.38) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL1967314 0.74 GAA (0.42) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL31381875 0.74 GAA (0.49) GAASMN1; SMN2ALDH1A1L3MBTL1GLA
SCHEMBL9418923 0.73 DGAT1 (0.36) GAASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL361851 0.73 ALDH1A1 (0.44) GAAALDH1A1PDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340493-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2016-05-17 US disclosed
US-9340493-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2016-05-17 US disclosed
US-9340493-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2016-05-17 US disclosed
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-07-24 US disclosed
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-07-24 US disclosed
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-07-24 US disclosed
US-8722686-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-05-13 US disclosed
US-8722686-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-05-13 US disclosed
US-8722686-B2 Hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-05-13 US disclosed
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents PFIZER INC. (US) 2011-07-21 US disclosed
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents PFIZER INC. (US) 2011-07-21 US disclosed
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents PFIZER INC. (US) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206651-A1 Hydroxamic Acid Derivatives Useful As Antibacterial Agents HCAR1, H1-0, HDAC1 GAA 156/4885SMN1; SMN2 3402/4885ALDH1A1 272/4885
US-20110178042-A1 Hydroxamic Acid Derivatives Useful as Antibacterial Agents HCAR1, HDAC1, H1-0 GAA 162/4885SMN1; SMN2 3282/4885ALDH1A1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.